No Detail Found!

Cytoreductive surgery versus systemic chemotherapy alone in isolated peritoneal carcinomatosis of colorectal origin

Author(s)
Melike Ozcelik Department of Medical Oncology, University of Health Sciences, Umraniye Education and Research Hospital,Istanbul,Turkey
Abdlkerim Oyman Department of Medical Oncology, University of Health Sciences, Umraniye Education and Research Hospital,Istanbul,Turkey
Ibrahim Cil Department of Medical Oncology, University of Health Sciences, Umraniye Education and Research Hospital,Istanbul,Turkey
Ozgul Duzgun Department of General Surgery, University of Health Sciences, Umraniye Education and Research Hospital,Istanbul,Turkey
Omer Faruk Ozkan Department of Medical Oncology, Dr. Lutfi K1rdar, Kartal Training and Research Hospital,Istanbul,Turkey
Murat Ayhan Department of Medical Oncology, Dr. Lutfi K1rdar, Kartal Training and Research Hospital,Istanbul,Turkey
Abstract
Objective: To compare the overall survival and progression-free survival of front-line cytoreductive surgery (CRs) ± hyperthermic intraperitoneal chemotherapy versus intensive systemic chemotherapy alone, in patients with isolated peritoneal carcinomatosis of colorectal origin. Study Design: Descriptive study. Place and Duration of Study:Departments of Medical Oncology and Surgical Oncology in University of Health Sciences, Umraniye Education and Research Hospital, from January 2017 to January 2020. Methodology: Clinicopathological data of patients presented with isolated peritoneal carcinomatosiswere categorised into two groups according to their treatment type as patients who received intensive systemic chemotherapy alone or underwent front-line CRS ± HIPEC. Overall and progression-free survival outcomes of the two approaches were quanti ed by survival analysis and compared with each other. The other collected variables were age, gender, performance status, tumor site and type of systemic chemotherapy. Results: Overall, 109 patients were included. The median progression-free survival of patients treated with cytoreductive surgery ± hyperthermic intraperitoneal chemotherapy was 12 months; whereas, it was 9 months in those treated with intensive systemic chemotherapy alone (p=0.011). The median overall survival was estimated as 32 months in patients treated with cytoreductive surgery ± hyperthermic intraperitoneal chemotherapy, compared with 23 months for those treated with systemic chemotherapy alone (p=0.715). Conclusion: Although not translated into overall survival gain, extended progression-free survival, maygive an advantage to cytoreductive surgery ± hyperthermic intraperitoneal chemotherapy when used with intensive systemic chemotherapy in the individualised treatment of isolated peritoneal carcinomatosis of colorectal carcinoma.
Publication Details
Page(s) 1308-1313
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 31, Issue: 11, Year: 2021

Request the full text from PASTIC

Keywords
colorectal carcinoma, Overall survival, Peritoneal carcinomatosis, Cytoreductive surgery, Hyperthermic intraperitoneal chemotherapy, Systemic chemotherapy
0

Citations

0

Downloads

82

Views